CIO Influence
CIO Influence News Deep Learning

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

PacBio, a leading developer of high-quality, highly accurate sequencing solutions and GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

“Over the past two years, PacBio has entered into both technology and research collaborations with leading research hospitals, health-organizations, and technology companies.We are honored to launch this new study with GeneDx and the University of Washington with the aim to bring together the power of the latest developments and capabilities applied to these critical populations,” said Christian Henry, President and Chief Executive Officer of PacBio. “Through this work, we move closer to our vision of creating a world where no family spends years on a diagnostic odyssey trying to understand the underlying genetic cause of their child’s disease or wondering whether future children will also be afflicted.”

GeneDx will perform WGS sequencing and analysis of samples from 350 people including 120 enrolled in the SeqFirst WGS study at Seattle Children’s Hospital, as well as their biological parents—duos and trios—as available.Both short- and long-read WGS will be performed as researchers explore whether novel variants not previously accessible via short-read sequencing technologies may underlie certain genetic conditions.SeqFirst, sponsored by GeneDx and in part funded by the Brotman Baty Institute, is a hub for genomic research and precision medicine, and a collaboration among three Seattle research institutions—UW MedicineSeattle Children’s Hospital, and Fred Hutchinson Cancer Center.

CIO INFLUENCE: CIO Influence Interview with Pete Lilley, Vice President and GM at Instaclustr

Long-read sequencing is a potential approach for interrogating whole human genomes and the novel variants inaccessible with short-read sequencing,” said Mike BamshadM.D., SeqFirst principal investigator, Professor and Chief of Genetic Medicine in the Department of Pediatrics at the University of Washington School of Medicine and Seattle Children’s Hospital.“We look forward to these collaborative efforts to expand our understanding of causative variation in DNA from patients with certain genetic conditions.”

GeneDx will use the PacBio Revio sequencing system to perform all long-read WGS sequencing and analysis for this study. The study intends to determine whether the increased accuracy, read-length and methylation insights offered by the Revio system will enable collaborators to better explore – and potentially increase – diagnostic yield. Aggregate sequencing data including novel variants and their frequencies identified through this study will be contributed to the Consortium of Long Read Sequencing (CoLoRS) database to advance scientific understanding of variant prevalence and classification.

“For more than twenty years, we have pioneered the development of clinical diagnostics, with the goal of ending the diagnostic odyssey for patients with rare genetic diseases,” said Gustavo StolovitzkyPh.D., Chief Science Officer at GeneDx. “We are excited to bring together GeneDx with PacBio and the University of Washington to explore the potential of innovative methods such as long-read sequencing to improve our ability to deliver a precise genetic diagnosis for these young children.”

CIO INFLUENCE: JFrog Software Supply Chain Platform Delivers 393% ROI According to Total Economic Impact Study

PacBio has previously partnered with Google to implement the deep learning method DeepConsensus on the Revio system and improve long-read whole genome sequencing performance with DeepVariantGoogle has expanded upon this earlier technical collaboration to contribute funding for this research study.

“These collaborations will allow us to realize goals from the origin of Google Health – for AI to find real applications in healthcare to help with critical and complex cases.By contributing to solutions for the most complex cases and the least served communities, we believe we can demonstrate the usefulness and importance of such technologies in better health outcomes. Our technology being embedded with Revio is a unique opportunity for us to make a difference with every run of the instrument,” said Greg Corrado, Head of Health AI at Google.

In addition to developing informatics methods, Google will fund key enablers (such as reagents) for this project. Google strongly believes such collaborations will help realize their mission to improve health outcomes by enabling collaborators to deliver what they are best at: highly accurate sequencing from PacBio, and clinical genetics support and patient care by GeneDx and the University of Washington.

CIO INFLUENCE: World Password Day: Password advice for CIOs

[To share your insights with us, please write to sghosh@martechseries.com]

Related posts

Anexinet Empowers Day & Zimmermann With New Hybrid Cloud Services

CIO Influence News Desk

Claroty Announces Rockwell Automation as Co-leader of $400 Million Series E Funding

CIO Influence News Desk

Cybersecurity Provider NordVPN Teams Rebrands as NordLayer

CIO Influence News Desk
StatCounter - Free Web Tracker and Counter